Background
==========

Health-related quality of life (HRQoL) questionnaires can be administered using a variety of methods, including face-to-face or telephone interviews, pencil and paper, computer touch-screen, or web-based. However, not all researchers may have equal access to all modes of administration (MOA). For example, despite the attractiveness of high-tech electronic methods, none of the 107 abstracts cited in PubMed for 2007 concerning the EORTC QLC-C30 HRQoL questionnaire reported having used a computer for data collection.

In addition, various MOA may not be equally practical for all respondents. For example, lack of language or computer skills may preclude the use of written questionnaires, whether pencil and paper or computer-based. It may also be sometimes necessary to combine multiple modes of administration in the same study, for example when conducting longitudinal research or combining data from various sources.

For these reasons, it is important to consider whether the measurement characteristics of various MOA\'s are equivalent, because, if this is not the case, then it would be difficult to compare outcomes across MOA\'s within or between studies. Many studies of varying designs, sizes, populations, and instruments have considered this issue, with generally similar results \[[@B1]-[@B9]\]. Namely, the effects of MOA on questionnaire measurement characteristics are generally not large. However, only two studies have investigated the effect of MOA on the EORTC QLQ-C30, one of the most widely used HRQoL questionnaires in oncology \[[@B10]-[@B15]\]. In a large (N = 855) observational study, Cheung et al. \[[@B14]\] investigated the effect of two MOA\'s, in-clinic interview with in-clinic paper-and-pencil, on the measurement properties on 4 multi-item scales of the QLQ-C30. Velikova et al. \[[@B15]\] used all 15 scales of the QLQ-C30 in a randomized, cross-over study of 149 patients, comparing in-clinic touch-screen with in-clinic paper & pencil administration. Despite their differences and limitations, these two studies each found several small, yet statistically significant, differences in scale mean scores as a function of MOA\'s (approximately 3-7 points on a 100 point scale). Both studies flagged the Emotional Functioning Scale as being potentially problematical.

The purpose of the current study was to investigate, in a controlled, randomized setting, the measurement characteristics of the EORTC QLQ C-30 under a variety of different, conventional MOA\'s.

Methods
=======

Study Sample
------------

The study sample employed in the current analysis was composed of participants in a study conducted by te Velde and colleagues that evaluated various instruments for HRQoL assessment in oncology \[[@B15],[@B16]\].

Patients
--------

The patient sample was composed of individuals with a variety of cancer diagnoses (primarily breast, colorectal, and lung) with various disease stages (local, loco-regional, or metastasized) who attended the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital for treatment. The data used in the current analysis were collected approximately 4 months after start of radio- or chemotherapy, during the third measurement wave (T3) in a longitudinal study.

Exclusion criteria included a life expectancy of less than 4 months, too ill to participate, participation in a concurrent HRQoL study, less than 18 years of age, and a lack of basic proficiency in Dutch. No restrictions were made with regard to age or performance status. Eligible patients received a full, verbal and written explanation of the purpose and procedures of the study. The study was approved by the local ethics committee, and written informed consent was obtained from all participating patients.

### Patient Characteristics

A number of variables, which were possibly relevant for the quality of patient ratings of HRQoL, were measured for the purpose of describing the sample of patients, as well as for assessing the quality of the randomization into three groups. Characteristics of the patients included: indicators of health (i.e., the Karnofsky Performance Status scale \[[@B17]\]), treatment and disease characteristics, comorbidity, sociodemographic data, and the EORTC QLQ-C30 questionnaire data collected during the previous (in-clinic) measurement wave at T2.

Procedure
---------

To assess the impact of different MOA\'s on the measurement performance of the EORTC QLQ-C30, patients were randomly assigned (with equal probabilities), during the first measurement wave of the study at T1, to one of three groups during the third measurement wave at T3: in-clinic written self-administration; telephone-based interviewer-administration, or mailed written self-administration.

Health-related quality of life (HRQoL) assessment
-------------------------------------------------

HRQoL was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30 (version 2.0)) \[[@B10]-[@B13]\]. It includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single items (dyspnea, insomnia, anorexia, constipation, diarrhea, and financial impact), and 1 global quality of life scale. The questionnaire employs a one-week time frame and a mix of dichotomous response categories (\"yes/no\"), 4-point Likert-type response scales (ranging from \"not at all\" to \"very much\"), and 7-point response scales (numbered visual analogue scales). The scoring procedures recommended by the EORTC \[[@B13]\] were used. All scale and single item scores of the QLQ-C30 were linearly transformed to a 0 to 100 scale. For the functioning scales, higher scores represent a better level of functioning; for the symptom measures, a higher score corresponds to a higher level of symptomology.

The QLQ-C30 has been shown to be reliable and valid in a range of patient populations and treatment settings. Across a number of studies, internal consistency estimates (Cronbach\'s coefficient α) of the multi-item scales exceeded or approached 0.70 \[[@B12]\]. Test-retest reliability coefficients have been found to range between 0.80 and 0.90 for most multi-item scales and single items \[[@B18]\]. Tests of validity have shown the QLQ-C30 to be responsive to meaningful between-group differences (e.g., local vs. metastatic disease, active treatment vs. follow-up) and changes in clinical status over time \[[@B10],[@B12]\].

Statistical Methods
-------------------

Mean scores and standard deviations for the QLQ-C30 scales, as well as for the characteristics of the patients were calculated. The internal consistency of the multi-item scales of the QLQ-C30 was assessed by Cronbach\'s coefficient alpha \[[@B19],[@B20]\].

Differences in scale/item means were tested by means of analysis of co-variance (ANCOVA), which allowed adjustment for possible confounders. To examine the magnitude of any observed difference between MOA\'s, mean difference scores between groups were then standardized by dividing them by the pooled standard deviation, in order to estimate an effect size \[[@B21]\]. Following Cohen \[[@B21]\], effect sizes of 0.20, 0.50, and 0.80 were considered small, medium, and large, respectively. Osoba et al. \[[@B22]\] determined that a difference of 10 or fewer points on the (re-scaled) QLQ-C30 scales could be viewed as being \"small\".

Levene\'s test for the equality of variances between groups was also calculated. Finally, multiple analysis of (co-)variance provided a multivariate test of differences between groups, with adjustment for possible confounders. For all tests, the type I error (alpha) significance level was set at 0.05.

Results
=======

Sample accrual (Figure [1](#F1){ref-type="fig"})
------------------------------------------------

![**Results of Patient accrual and randomization**.](1477-7525-8-35-1){#F1}

During the study period, 614 patients who met the eligibility criteria were invited to participate in the study, of whom 483 (79%) accepted at T1. Reasons for declining study participation included: (a) the study was perceived as too emotionally burdensome (n = 54); (b) perceived lack of time (n = 22); (c) lack of interest (n = 18); or (d) being too ill (n = 10). The remaining 29 patients had a variety of other reasons. Patients declining participation were, on average, older (mean age 65 years vs. 57 years), were less frequently married (59% vs. 76%), and more often had compulsory education only (91% vs. 82%), than those who participated.

Of the 483 patients initially enrolled in the study, and randomized at the first assessment point T1, 375 (78%) remained available for the actual measurement at T3, which was used for the present analysis. The primary reasons for patient attrition were severe illness (*n*= 36) or death (*n*= 35). Patients lost to follow-up were more likely to have metastatic disease, and their KPS was 10 to 30 points lower than patients who continued participation. The average time between Tl and T3 was 128 days.

However, after randomization, 11 patients declined to participate in the MOA condition to which they were assigned, and 50 patients randomized to the in-clinic condition did not attend the hospital for a follow-up visit that coincided with this -third- assessment point. These patients were also excluded from further analysis.

Statistical Power
-----------------

We determined that the present sample size would be able to detect a \"medium\" effect size for differences in means (d = 0.50) between two groups with a power exceeding 90%, (assuming a two-sided test with a significance of 5%) \[[@B21]\].

Sample characteristics (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"})
-----------------------------------------------------------------------------------------

###### 

Patient sample characteristics (n = 314) for 3 MOA groups

  ----------------------------------------------------------------------------------------------------------------
  Individual Characteristics   Paper & pencil at home\   Telephone\         Paper & pencil in-clinic\   
                               (n = 132)                 (n = 121)          (n = 61)                    
  ---------------------------- ------------------------- ------------------ --------------------------- ----------
                               **Means (s.d.)**          **Means (s.d.)**   **Means (s.d.)**            **Sig.**

                                                                                                        

  Age                          56.6(12.9)                57.0(12.0)         54.1(11.5)                  .30

  KPS                          77.4(14.4)                78.1(13.7)         78.0(15.0)                  .93

                                                                                                        

                               **N(%)**                  **N(%)**           **N(%)**                    

                                                                                                        

  Sex (%)                                                                                               

   Male                        48(36%)                   47(39%)            16(27%)                     .23

                                                                                                        

  Marital Status                                                                                        

   Single                      11(8%)                    9(8%)              6(10%)                      .92

   Married                     99(75%)                   97(81%)            44(73%)                     

  Divorced                     10(8%)                    7(6%)              5(8%)                       

   Widowed                     12(9%)                    7(6%)              5(8%)                       

                                                                                                        

  Education                                                                                             

   \<10 years                  70(53%)                   69(58%)            32(53%)                     .21

   10-15 years                 39(30%)                   35(29%)            12(20%)                     

   \>15 years                  23(17%)                   16(13%)            16(27%)                     

                                                                                                        

  Employed                                                                                              

   Yes                         50(38%)                   41(35%)            19(32%)                     .70

                                                                                                        

  Stage of Disease\*                                                                                    

   Local/regional              86(66%)                   73(61%)            28(47%)                     .04

                                                                                                        

  Treatment\*\*                                                                                         

   Chemotherapy                56(42%)                   50(41%)            44(73%)                     \<.00

   Radiotherapy                70(53%)                   67(55%)            15(25%)                     

   RT+CT/other                 6(5%)                     4(3%)              1(2%)                       

                                                                                                        

  Comorbidity                                                                                           

   Yes                         74%                       74%                69%                         .76

                                                                                                        

  Primary Site                                                                                          

   Breast                      48(36%)                   49(41%)            32(53%)                     .11

   Colorectal                  38(29%)                   31(26%)            10(17%)                     

   Lung                        36(27%)                   29(24%)            9(15%)                      

   Other                       10(8%)                    12(10%)            9(15%)                      
  ----------------------------------------------------------------------------------------------------------------

\* p \< 0.05 \*\* p \< 0.01

###### 

Patient sample characteristics (n = 314) for 3 MOA groups at Pretest *(T2)*

  ---------------------- ----------------------------- ------------------- ------------------------------- ------------------- ----------------- ------------------- ----------
  **QLQ-C30**\           **Paper & pencil at home**\   **Telephone**\      **Paper & pencil in-clinic**\                                                             
  **at pre-test (T2)**   **(n = 132)**                 **(n = 121)**       **(n = 61)**                                                                              

                                                                                                                                                                     

                         **Mean (s.d.)**               **%**\              **Mean (s.d.)**                 **%**\              **Mean (s.d.)**   **%**\              **Sig.**
                                                       **floor/ceiling**                                   **floor/ceiling**                     **floor/ceiling**   

                                                                                                                                                                     

  Physical function      62.0(28.9)                    2%/23%              69.9(23.0)                      2%/26%              66.8(24.2)        2%/23%              .052

  Role function          59.2(31.3)                    4%/27%              67.9(28.3)                      5%/36%              66.9(28.6)        12%/35%             .050

  Cognitive function\*   80.0(18.4)                    0%/43%              82.5(18.9)                      1%/50%              87.2(14.4)        0%/39%              .038

  Emotional function     74.4(21.0)                    1%/20%              77.7(19.6)                      1%/36%              78.6(18.7)        0%/26%              .294

  Social function        76.5(27.6)                    2%/52%              82.8(20.5)                      1%/60%              81.7(22.7)        2%/51%              .103

  GlobalHealth/QoL       61.5(22.0)                    1%/6%               67.2(19.5)                      1%/12%              66.1(19.6)        0%/8%               .078

  Fatigue                45.6(26.0)                    13%/3%              38.2(23.5)                      21%/3%              40.1(26.9)        15%/3%              .060

  Nausea/vomitig         14.1(21.3)                    69%/1%              10.4(19.0)                      76%/1%              13.4(18.5)        62%/2%              .321

  Pain\*\*               30.5(29.9)                    30%/3%              24.7(26.2)                      45%/4%              14.8(20.4)        46%/0%              .001

  Dyspnea                20.1(27.9)                    55%/4%              18.1(24.0)                      55%/0%              18.0(24.0)        51%/2%              .785

  Insomnia               30.0(33.8)                    52%/8%              29.4(31.8)                      63%/2%              21.9(28.5)        57%/3%              .226

  Anorexia               24.2(29.8)                    72%/2%              19.1(29.3)                      72%/5%              22.2(29.9)        66%/2%              .392

  Constipation           11.8(23.8)                    83%/2%              7.8(19.2)                       87%/1%              12.0(21.1)        82%/0%              .268

  Diarrhea               10.8(21.7)                    85%/1%              11.7(22.7)                      85%/0%              4.4(13.0)         87%/0%              .074

  Financial              8.2(19.0)                     82%/1%              5.6(13.9)                       89%/2%              3.3(11.7)         90%/0%              .117
  ---------------------- ----------------------------- ------------------- ------------------------------- ------------------- ----------------- ------------------- ----------

\* p \< 0.05 \*\* p \< 0.01

Characteristics of the patients in each of the three MOA groups are presented in Table [1](#T1){ref-type="table"}. Pre-test HRQoL measurements, taken at T2, are presented in Table [2](#T2){ref-type="table"}. Of those patients remaining in the study at T3, very few data were missing, not exceeding 3% for any of the QLQ-C30 scales for any of the three conditions (data not shown). Mainly due to the loss of the 50 patients randomized to the in-clinic condition, there was an imbalance in the number of patients per group, and in the distribution of stage of disease, type of treatment, and several previous QLQ-C30 scale scores between the three groups. These 50 dropout-patients differed from the patients remaining in the in-clinic condition primarily in terms of type of treatment (p \< 0.05, after adjustment for other predictors).

Internal Consistency of the QoL proxy scales (Table [3](#T3){ref-type="table"})
-------------------------------------------------------------------------------

###### 

Cronbach\'s alpha\'s for multi-item Scales for three MOA groups

  ----------------------------------------------------------------------------------------
  EORTC QLQ-C30\        Paper & pencil at home\   Telephone\   Paper & pencil in-clinic\
  Multi-item Scales     (N = 132)                 (N = 121)    (N = 61)
  --------------------- ------------------------- ------------ ---------------------------
  Physical function     0.69                      0.71         0.69

  Role function\* ^&^   0.87                      0.80         0.93

  Cognitive function    0.57                      0.64         0.57

  Emotional function    0.86                      0.86         0.84

  Social function       0.78                      0.64         0.81

  Global health/QoL     0.84                      0.84         0.89

  Fatigue               0.87                      0.87         0.88

  Nausea/vomiting       0.73                      0.75         0.64

  Pain                  0.86                      0.87         0.79
  ----------------------------------------------------------------------------------------

\* p \< 0.05

\*\* p \< 0.01

& The significant difference in this comparison is between the telephone versus the in-clinic Paper & Pencil condition

Cronbach\'s alpha\'s for the multi-item scales for each group were generally adequate (i.e., \> 0.70) in the large majority of cases. The consistent exception was the Cognitive Functioning scale; something that has been observed in many other studies. There was a significant difference between the in-clinic paper-and-pencil and the telephone conditions for the Role Functioning (RF) scale, even though this scale performed rather well (alpha \> = 0.8) for all three conditions.

Mean QLQ-C30 scale score differences (Table [4](#T4){ref-type="table"})
-----------------------------------------------------------------------

###### 

Adjusted\# Means (+s.e.) for three MOA groups

  ---------------------------------------------------------------------------------------------------------------
  EORTC QLQ-C30\             Paper & pencil at home\   Telephone\        Paper & Pencil in clinic\   
  All Scales                 (N = 132)                 (N = 121)         (N = 61)                    
  -------------------------- ------------------------- ----------------- --------------------------- ------------
                             **Mean (s.e.)**           **Mean (s.e.)**   **Mean (s.e.)**             **Sig.\#**

                                                                                                     

  Physical function          68.9(2.9)                 67.1(3.0)         65.3(3.6)                   .47

  Role function              61.4(3.3)                 62.2(3.3)         60.4(3.9)                   .86

  Cognitive function         86.2(2.7)                 86.0(2.8)         84.8(3.3)                   .87

  Emotional function\* ^&^   74.1(2.7)                 79.5(2.8)         75.0(3.3)                   .04

  Social function            79.1(3.1)                 79.2(3.2)         76.9(3.8)                   .76

  Global Health/QoL          64.7(2.6)                 66.0(2.7)         64.5(3.2)                   .79

  Fatigue                    41.0(3.2)                 41.9(3.2)         45.3(3.8)                   .42

  Nausea/vomiting            6.9(2.9)                  6.2(3.0)          7.5(3.5)                    .90

  Pain                       33.6(3.6)                 33.1(3.7)         26.0(4.4)                   .11

  Dyspnea                    24.4(3.4)                 26.4(3.5)         28.6(4.2)                   .48

  Insomnia                   30.5(4.3)                 22.3(4.4)         27.3(5.2)                   .06

  Anorexia                   8.7(3.9)                  13.4(4.0)         13.0(4.7)                   .29

  Constipation               4.2(3.1)                  4.8(3.1)          1.7(3.7)                    .61

  Diarrhea                   6.2(2.5)                  6.4(2.6)          5.7(3.1)                    .97

  Financial                  10.4(2.9)                 8.7(2.9)          5.8(3.5)                    .30
  ---------------------------------------------------------------------------------------------------------------

\*p \< 0.05 \*\* p \< 0.01

\# adjusted for covariates in Tables 1 and 2

& overall effect size for Emotional Function scale are 0.16 for overall effect (Cohen\'s f, based on partial eta squared) and 0.31, 0.14, 0.19 (Cohen\'s d) for the \"telephone vs. paper & pencil at home\", the \"paper & pencil at home vs. pencil & paper in-clinic\", and the \"telephone vs. paper & pencil in-clinic\" pairs of conditions, respectively.

The adjusted means and standard errors of the three MOA groups for each of the 15 QLQ-C30 scales are presented in Table [4](#T4){ref-type="table"}. After adjustment for the possible confounders shown in Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, significant group differences were found only for Emotional Functioning (EF). The telephone condition had the highest EF, and the paper-and-pencil at-home condition the lowest. The un-adjusted mean difference between these two conditions was approximately 6 points, the adjusted mean difference being only 5.4 points. The pair-wise Cohen\'s d\'s for the \"telephone vs. paper & pencil at home\", the \"paper & pencil at home vs. pencil & paper in-clinic\", and the \"telephone vs. paper & pencil in-clinic\" conditions were 0.31, 0.14, 0.19, respectively. These results qualify the MOA effect for the EF scale as being \"small\".

An additional analysis was conducted, adding a fourth group of patients to the above analyses of differences between means. This fourth group consisted of the patients who were not available for the in-clinic paper & pencil condition because they did not return to the clinic at T3. These patients were invited to complete the questionnaire in the same manner as the \"paper & pencil at home\" condition. Results indicated that patients in this fourth group had significantly poorer scores for the EF and SL scales as compared to the\" telephone\" condition, and did not differ from the original paper & pencil conditions (data not shown).

Miscellaneous statistical tests
-------------------------------

A Levene test for difference in variances between the groups was significant for Pain, Appetite loss, and Financial Difficulties (p \< 0.05). A multivariate analysis of variance (Pillai\'s trace/Wilk\'s lambda, with adjustment for confounders) found no significant difference (p = 0.40) between the three groups. (Data not presented.)

Discussion
==========

In this study we investigated several measurement properties of the EORTC QLQ-C30 questionnaire under various MOA\'s. Despite the widespread use of the EORTC QLQ-C30, only two studies had previously investigated this matter. One large observational study considered 4 of the QLQ-C30 multi-item scales \[[@B14]\], while the other study used a randomized, cross-over design, but with a much smaller sample size, and with only two (in-clinic) conditions \[[@B15]\].

The present study of a heterogeneous population of 375 cancer patients considered three conditions (at-home as well as in-clinic) in a randomized, between-subjects trial.

Remarkably, all three of these studies flag the Emotional Functioning (EF) scale as yielding a small, yet statistically significant difference as a function of MOA, with patients in paper-and-pencil MOA\'s reporting lower levels of emotional functioning. The present study also found a small, yet significant difference in Cronbach\'s alpha for the Role Functioning scale; however, the RF scale performed quite adequately for all three conditions.

We suspect that the slightly lower EF scale scores in paper-and-pencil conditions may be related to the \"demand characteristics\" associated with different MOA\'s. Specifically, patients, who are encouraged to react quickly and/or who are required to interact with an interviewer, may be stimulated to present more socially desirable responses than those patients allowed to reflect on their level of emotional functioning and whose responses to the questions are not the subject of direct observation. For example, patients are asked in the QLQ-C30 whether they are depressed, which is not a directly observable state, and whose admission might be felt as being potentially stigmatizing.

Many studies of varying designs, sizes, populations, and instruments have considered the issue of measurement characteristics of various MOA, with generally similar results. Namely, while various MOA may differ in costs, completion rates, etc., the effects of MOA on questionnaire measurement characteristics are generally of \"small to medium\" size, if found at all. This would suggest that one should exercise caution when mixing MOA\'s while investigating effects of similar magnitudes.

A limitation associated with the present investigation concerns the post-randomization dropout of patients prior to assessment. This occurred primarily in the in-clinic condition. Almost 50% of the patients allocated to this condition did not return to the clinic in time for the present study. This differential drop-out (apparently) lead to group differences in patient characteristics, such as treatment, stage of disease, and pre-randomization HRQoL measures. However, we believe that adjustment for these patient characteristics in the statistical analyses was largely able to correct for these group differences. An additional, sensitivity analysis included these in-clinic dropouts, who were approached via \"pencil & paper at home\". This analysis re-flagged the EF scale, as well as the SL scale, indicating that the \"telephone\" MOA yielded a more positive result than pencil & paper conditions (which did not differ from each other). These findings are commensurate with the finding reported above.

A second limitation concerns the use of version 2.0 of the EORTC QLQ-C30. There are, namely, slight differences with the current version 3.0, involving the number of response categories for the Physical Function scales. This might slightly limit the generalizability of these results to users of version 3.0.

Conclusions
===========

In conclusion, the findings of this investigation indicate that the 3 modes of administration studied here have little effect on the internal consistency or the mean responses on the EORTC QLQ-C30 scales. The exception to this generalization is the Emotional Functioning scale, which exhibited small, yet significant, differences between various administration modes. These results suggest that, with the possible exception of assessment of emotional functioning, there is little reason for concern about the comparison of QLQ-C30 results within or across studies as a function of mode of administration.
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